News

World Pharma Today || Foundational partnership with Paradigm4 enables Alnylam Pharmaceuticals to rapidly accelerate RNAi- based drug target discovery

Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline.

whitepages icon x

GenomeWeb: Paradigm4 Moves Into Single-Cell Data, Helps Pharma Address COVID-19

Neil Versel

whitepages icon x

Pharma’s Almanac || What do you consider the biggest challenge that the pharma/biopharma industry currently faces?

Marilyn Matz, Chief Executive Officer and Co-Founder, Paradigm4 “Genomics’ role in the life science vision “is only as credible as its implementation,”

whitepages icon x

Biocompare | Are We Ready to Embrace Precision Medicine?

Precision medicine is one of the most talked about trends in healthcare. The promise is improved health outcomes and patient satisfaction, gained through an understanding of individual variability in genes, environment, and lifestyle. Recent commentators suggest that many of the technologies required to realize this goal already exist—and predict much